KE, K., L, C., S, W., EE, B., KA, M., TM, T., . . . KM, S. (2026). Teplizumab treatment for stage 2 type 1 diabetes: A real-world evaluation of metabolic and immunological outcomes. Diabetologia, 69(5), 1164. https://doi.org/10.1007/s00125-025-06646-6
Chicago Style (17th ed.) CitationKE, Karakus, et al. "Teplizumab Treatment for Stage 2 Type 1 Diabetes: A Real-world Evaluation of Metabolic and Immunological Outcomes." Diabetologia 69, no. 5 (2026): 1164. https://doi.org/10.1007/s00125-025-06646-6.
MLA (9th ed.) CitationKE, Karakus, et al. "Teplizumab Treatment for Stage 2 Type 1 Diabetes: A Real-world Evaluation of Metabolic and Immunological Outcomes." Diabetologia, vol. 69, no. 5, 2026, p. 1164, https://doi.org/10.1007/s00125-025-06646-6.
Warning: These citations may not always be 100% accurate.
